PEPTIDESTAT
ApprovedClinical / approved drugSubcutaneousEvidence 5/5

Lanreotide

Also known as: Somatuline Depot, Somatuline Autogel

Lanreotide binds with high affinity to somatostatin receptors 2 and 5, mimicking native somatostatin to suppress growth hormone, IGF-1 and various neuroendocrine and gut hormones.

Read guideBuy / compare source
Lanreotide
Drug class
Long-acting somatostatin analog (cyclic octapeptide)
Primary targets
SSTR2, SSTR5
Dose reference
Per FDA label (not a recommendation): acromegaly 60-120 mg deep subcutaneously every 4 weeks (typically starting at 90 mg); GEP-NET and carcinoid syndrome 120 mg every 4 weeks.
Half-life
Depot-dominated: apparent terminal elimination of about 23-30 days due to slow release from the subcutaneous gel depot
Developer / origin
Ipsen
Reference year
2007
Evidence score
5/5 - Strong, FDA-approved with randomized evidence

Approved uses

  • Long-term treatment of acromegaly in patients with inadequate response to or ineligibility for surgery and/or radiotherapy
  • Unresectable, well- or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival
  • Treatment of carcinoid syndrome (reduces need for short-acting somatostatin analog rescue therapy)
Evidence 5/5

Strong, FDA-approved with randomized evidence

Lanreotide is an FDA-approved long-acting somatostatin analog with label-backed indications in acromegaly, GEP-NETs and carcinoid syndrome, supported by randomized trial evidence including the phase 3 CLARINET trial showing prolonged progression-free survival.

Approved medication with substantial human clinical evidence.

Evidence basis

  • FDA prescribing information (Somatuline Depot) with three approved indications since 2007
  • Phase 3 CLARINET randomized placebo-controlled trial (NEJM 2014, n=204) showing significantly prolonged progression-free survival in metastatic enteropancreatic NETs
  • Placebo-controlled carcinoid syndrome data (ELECT) and acromegaly registry/dose-response evidence
  • Well-characterized SSTR2/SSTR5 receptor pharmacology

How to read this entry

Dose references and half-life values are pulled from trial protocols, labels, reviews, or published summaries where available. They are context for research and comparison, not a personal dosing recommendation.

Status matters: approved drugs have regulated indications; investigational compounds are still being studied; research-only peptides do not have established human dosing, safety, or efficacy for consumer use.

Lanreotide guides

Read the matching guide or adjacent research pages for more context.

Lanreotide Peptide: Somatuline Depot Uses, Evidence and Safety LimitsLanreotide is an FDA-approved long-acting somatostatin analog peptide with strong label-backed evidence in acromegaly and neuroendocrine tumors.Abaloparatide Peptide: Tymlos, PTHrP Analog Uses and Safety LimitsAbaloparatide is an FDA-approved PTHrP(1-34) analog peptide that builds bone in high-risk osteoporosis, backed by the ACTIVE and ATOM trials with clear duration and safety limits.Atosiban Peptide: Tractocile, Oxytocin Antagonist Tocolytic for Preterm LaborAtosiban is an EU-approved oxytocin and vasopressin receptor antagonist peptide used intravenously as a short-term tocolytic to delay preterm labor.Bivalirudin Peptide: Angiomax Direct Thrombin Inhibitor GuideBivalirudin is an FDA-approved, hirudin-derived bivalent direct thrombin inhibitor used as a short-acting intravenous anticoagulant during percutaneous coronary intervention.

Peptide calculators

Use calculators for concentration, unit conversion and repeated-dose accumulation math.

Peptide reconstitution calculatorCalculate concentration, draw volume and syringe units from vial strength and BAC water.Open toolPeptide accumulation calculatorModel repeated dosing schedules with half-life, interval, peak and trough estimates.Open toolPeptide unit converterConvert mg, mcg, optional IU and syringe units from one reconstituted vial setup.Open toolPeptide chemistry calculatorAnalyze sequence length, molecular weight, composition, charge, hydropathy and notation.Open tool

Compare with related peptides

Stay inside the same research category and compare mechanism, status and evidence quality.

Larazotide

Larazotide acetate, AT-1001

2/5
Clinical / approved drugInvestigational

An oral, gut-restricted peptide that antagonizes zonulin signaling to limit gluten-driven intestinal tight-junction permeability in celiac disease.

DetailsGuide

Teriparatide

Forteo, Bonsity, PTH 1-34

4/5
Clinical / approved drugApproved

Once-daily injection produces intermittent activation of the PTH1 receptor on osteoblasts, preferentially stimulating bone formation over resorption to increase bone mass.

DetailsGuide
4/5
Clinical / approved drugApproved

Abaloparatide is a PTHrP(1-34) analog that agonizes the PTH1 receptor with preference for its transient RG conformation, activating cAMP signaling to stimulate osteoblast-driven new bone formation.

DetailsGuide

Calcitonin

Miacalcin, Fortical, salmon calcitonin

3/5
Clinical / approved drugApproved

Calcitonin activates the calcitonin receptor on osteoclasts to inhibit bone resorption and lower blood calcium, with additional actions on the kidney and gastrointestinal tract.

DetailsGuide

Research & educational purposes only

The information on PeptideStat is for educational and research purposes only and is not medical advice. Many peptides discussed are research compounds not approved for human use. Always consult a qualified healthcare professional before making any health decisions. Articles may contain affiliate links — we may earn a commission at no extra cost to you.